Regeneron Pharmaceuticals, Inc. (REGN)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Regeneron Pharmaceuticals, Inc. (REGN)
Go deeper and ask any question about REGN
Company Performance
Current Price
as of Sep 18, 2024$1138.81
P/E Ratio
30.16
Market Cap
$123.47B
Description
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Metrics
Overview
- HQTarrytown, NY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerREGN
- Price$1138.81-0.69%
Trading Information
- Market Cap$123.47B
- Float96.44%
- Average Daily Volume (1m)406,032
- Average Daily Volume (3m)460,970
- EPS$40.31
Company
- Revenue$13.49B
- Rev Growth (1yr)12.32%
- Net Income$1.43B
- Gross Margin83.06%
- EBITDA Margin34.23%
- EBITDA$1.21B
- EV$114.18B
- EV/Revenue8.46
- P/E30.16
- P/S9.74